Abstract
Background
Studies to date have yielded inconclusive results as to whether maternal medical history during pregnancy, and a child’s early-life medical history contribute to the development of childhood brain tumours (CBTs). This study examined associations between maternal and childhood medical history and the risk of CBTs.
Methods
The Childhood Brain Tumour Epidemiology Study of Ontario (CBREO) examined children 0–15 years of age with newly diagnosed CBTs from 1997 to 2003. Multivariable logistic regression analysis determined associations for prenatal medications and childhood medical history, adjusted for child’s demographics, and maternal education. Analyses were stratified by histology. A latency period analysis was conducted using 12- and 24-month lead times.
Results
Maternal intake of immunosuppressants during the prenatal period was significantly associated with glial tumours (OR 2.73, 95% CI 1.17–6.39). Childhood intake of anti-epileptics was significantly associated with CBTs overall, after accounting for 12-month (OR 8.51, 95% CI 3.35–21.63) and 24-month (OR 6.04, 95% CI 2.06–17.70) lead time before diagnosis. No associations for other medications were found.
Conclusions
This study underscores the need to examine potential carcinogenic effects of the medication classes highlighted and of the indication of medication use. Despite possible reverse causality, increased CBT surveillance for children with epilepsy might be warranted.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


Data availability
Data are available on request due to privacy/ethical restrictions.
Code availability
All statistical analyses were completed using STATA version 15.0. The code is available upon request from the corresponding author.
Change history
13 September 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41416-023-02415-7
References
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer observatory: cancer today [Internet]. International Agency for Research on Cancer. 2020. https://gco.iarc.fr/today.
Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18:719–31.
Association of the Nordic Cancer Registries. NORDCAN [Internet]. 2023. https://nordcan.iarc.fr/en.
Youlden DR, Baade PD, Green AC, Valery PC, Moore AS, Aitken JF. The incidence of childhood cancer in Australia, 1983–2015, and projections to 2035. Med J Aust. 2020;212:113–20.
Ostrom QT, Fahmideh MA, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21:1357–75.
Johnson KJ, Cullen J, Barnholtz-Sloan JS, Ostrom QT, Langer CE, Turner MC, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomark Prev. 2014;23:2716–36.
Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of brain and other CNS tumors. Curr Neurol Neurosci Rep. 2021;21:1–12.
Leong C, Chateau D, Dahl M, Falk J, Katz A, Bugden S, et al. Prescription medication use during pregnancies that resulted in births and abortions (2001-2013): a retrospective population-based study in a Canadian population. PLoS ONE. 2019;14:e0211319.
Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;1:e1–8.
Brender JD, Kelley KE, Werler MM, Langlois PH, Suarez L, Canfield MA. Prevalence and patterns of nitrosatable drug use among U.S. women during early pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91:258–64.
Schüz J, Weihkopf T, Kaatsch P. Medication use during pregnancy and the risk of childhood cancer in the offspring. Eur J Pediatr. 2007;166:433–41.
Momen NC, Olsen J, Gissler M, Kieler H, Haglund B, Li J. Exposure to systemic antibacterial medications during pregnancy and risk of childhood cancer. Pharmacoepidemiol Drug Saf. 2015;24:821–9.
Bonaventure A, Simpson J, Ansell P, Roman E, Lightfoot T. Prescription drug use during pregnancy and risk of childhood cancer—is there an association. Cancer Epidemiol. 2015;39:73–8.
Fitton CA, Steiner MFC, Aucott L, Pell JP, Mackay DF, Fleming M, et al. In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review. J Hypertens. 2017;35:2123–37.
Lydakis C, Lip GYH, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541–7.
Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. JAMA Psychiatry. 2020;77:1246–55.
Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, Ito S. Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin Pharm Ther. 2015;98:417–41.
Fan H, Gilbert R, O’Callaghan F, Li L. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368:m766.
Fan H, Li L, Wijlaars L, Gilbert RE. Associations between use of macrolide antibiotics during pregnancy and adverse child outcomes: a systematic review and meta-analysis. PLoS ONE. 2019;14:e0212212.
Vuong AM, Shinde MU, Brender JD, Shipp EM, Huber JC, Sharkey JR, et al. Prenatal exposure to nitrosatable drugs, dietary intake of nitrites, and preterm birth. Am J Epidemiol. 2016;183:634–42.
Cardy AH, Little J, McKean-Cowdin R, Lijinsky W, Choi NW, Cordier S, et al. Maternal medication use and the risk of brain tumors in the offspring: The SEARCH international case-control study. Int J Cancer. 2006;118:1302–8.
Connelly JM, Malkin MG. Environmental risk factors for brain tumors. Curr Neurol Neurosci Rep. 2007;7:208–14.
Hjorth S, Hemmingsen CH, Bénévent J, Broe A, Pottegaard A, Mørch LS, et al. Maternal medication use and childhood cancer in offspring—systematic review and considerations for researchers. Am J Epidemiol. 2021;190:2487–99.
Preston-Martin S, Yu MC, Benton B, Henderson BE. N-nitroso compounds and childhood brain tumors: a case-control study. Cancer Res. 1982;42:5240–5.
Cahoon EK, Inskip PD, Gridley G, Brenner AV. Immune-related conditions and subsequent risk of brain cancer in a cohort of 4.5 million male US veterans. Br J Cancer. 2014;110:1825–33.
Oksuzyan S, Crespi CM, Cockburn M, Mezei G, Kheifets L. Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California. Cancer Epidemiol. 2013;37:402–9.
Volkova A, Ruggles K, Schulfer A, Gao Z, Ginsberg SD, Blaser MJ. Effects of early-life penicillin exposure on the gut microbiome and frontal cortex and amygdala gene expression. iScience. 2021;24:102797.
Howe GR, Burch JD, Chiarelli AM, Risch HA, Choi BCK. An exploratory case-control study of brain tumors in children. Cancer Res. 1989;49:4349–52.
Gumey JG, Mueller BA, Preston-Martin S, Mc Daniel AM, Holly EA, Pogoda JM, et al. A study of pediatric brain tumors and their association with epilepsy and anticonvulsant use. Neuroepidemiology. 1997;16:248–55.
Goldhaber MK, Selby JV, Hiatt RA, Quesenberry CP. Exposure to barbiturates in utero and during childhood and risk of intracranial and spinal cord tumors. Cancer Res. 1990;50:4600–3.
Cordier S, Iglesias M‐J, Le Goaster C, Guyot M‐M, Mandereau L, Hemon D. Incidence and risk factors for childhood brain tumors in the Ile de France. Int J cancer. 1994;59:776–82.
Olsen JH, Boice JD, Jensen JPA, Fraumeni JF. Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst. 1989;81:803–9.
Cheng S, McLaughlin JR, Brown MC, Al-Sawaihey H, Rutka J, Bouffet E, et al. Childhood head trauma and the risk of childhood brain tumours: a case-control study in Ontario, Canada. Int J Cancer. 2021;150:795–801.
Yanik EL, Smith JM, Shiels MS, Clarke CA, Lynch CF, Kahn AR, et al. Cancer risk after pediatric solid organ transplantation. Pediatrics. 2017;139:20163893.
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, et al. The evolutionary history of 2,658 cancers. Nature. 2020;578:122–8.
Zhang Y, Chen F, Donehower LA, Scheurer ME, Creighton CJ. A pediatric brain tumor atlas of genes deregulated by somatic genomic rearrangement. Nat Commun. 2021;12:937.
Ullrich NJ, Pomeroy SL, Kapur K, Manley PE, Goumnerova LC, Loddenkemper T. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015;56:1599–604.
Sánchez Fernández I, Loddenkemper T. Seizures caused by brain tumors in children. Seizure. 2017;44:98–107.
Salminen J, Tammela T, Auvinen A, Murtola T. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27:637–45.
Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 2005;128:7–17.
Günaldi M, Paydaş S, Afşar ÇU, Duman BB, Erçolak V, Haksöyler V. Karbamazepin ve multipl miyelom: Olasi i̇lişki. Turkish J Hematol. 2013;30:83–4.
Kristensen KB, Pedersen SA, Schmidt SAJ, Pottegård A. Use of antiepileptic drugs and risk of skin cancer: a nationwide case-control study. J Am Acad Dermatol. 2020;82:326–35.
Stritzelberger J, Lang JD, Mueller TM, Reindl C, Westermayer V, Kostev K, et al. Anti-seizure medication is not associated with an increased risk to develop cancer in epilepsy patients. J Neurol. 2021;268:2185–91.
Kim H-B, Myung S-K, Park YC, Park B. Use of benzodiazepine and risk of cancer: a meta-analysis of observational studies. Int J Cancer. 2017;140:513–25.
Miyawaki I, Moriyasu M, Funabashi H, Yasuba M, Matsuoka N. Mechanism of clobazam-induced thyroidal oncogenesis in male rats. Toxicol Lett. 2003;145:291–301.
McCredie M, Maisonneuve P, Boyle P. Antenatal risk factors for malignant brain tumours in new south wales children. Int J Cancer. 1994;56:6–10.
Stålberg K, Haglund B, Strömberg B, Kieler H. Prenatal exposure to medicines and the risk of childhood brain tumor. Cancer Epidemiol. 2010;34:400–4.
Bauer AZ, Swan SH, Kriebel D, Liew Z, Taylor HS, Bornehag CG, et al. Paracetamol use during pregnancy — a call for precautionary action. Nat Rev Endocrinol. 2021;17;757–766.
Kramer S, Ward E, Meadows A, Malone K. Medical and drug risk factors associated with neuroblastoma: a case-control study. J Natl Cancer Inst. 1987;78:797–804.
Momen NC, Munk-Olsen T, Li J, Ingstrup KG, Olsen J, Bergink V, et al. Antidepressant use during pregnancy and childhood cancer in the offspring. Pharmacoepidemiol Drug Saf. 2018;27:114–8.
Centers for Disease Control and Prevention (CDC). Prevalence of self-reported epilepsy—United States, 1986–1990. JAMA. 1994;272:1893.
Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821–5.
Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents-United States, 1999-2014. J Am Med Assoc. 2018;319:2009–20.
Acknowledgements
This study was supported by a research grant with funds provided by the Canadian Institute of Health Research and the Canadian Cancer Society. We thank E. Badalian, H. White, J. Polzer, R. Gaudet, and W. Medved for their contributions to conducting the study interviews.
Funding
None.
Author information
Authors and Affiliations
Contributions
RJH conceived the study and its design. JRM, MCB, JR, EB, MG and DM contributed to the data collection. SC completed the statistical analysis and drafted the manuscript with RJH and MCB. All authors contributed to study organisation and result interpretation. All authors reviewed the manuscript and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
Informed consent was obtained from all participants. The study was approved by the Mount Sinai Hospital Research Ethics Board (REB 20-0055-E).
Consent for publication
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: In this article the name of Mark Greenberg has been corrected.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cheng, S., McLaughlin, J.R., Brown, M.C. et al. Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada. Br J Cancer 129, 318–324 (2023). https://doi.org/10.1038/s41416-023-02281-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-023-02281-3